Moreover, we estimated different signatures of major pathways between ER/PR− and ER/PR+ clusters and found that samples with ER/PR+ and ER/PR− showed statistically significant differences in gene expression, tumor immune microenvironment, and response to drug treatment. The gene discussed is ESR1; the disease is neoplasm.